- Home
- INCY vs TLN Comparison
INCY vs TLN Comparison
Compare INCY & TLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- TLN
- Stock Information
- Founded
- INCY 1991
- TLN 2015
- Country
- INCY United States
- TLN United States
- Employees
- INCY N/A
- TLN N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- TLN Electric Utilities: Central
- Sector
- INCY Health Care
- TLN Utilities
- Exchange
- INCY Nasdaq
- TLN Nasdaq
- Market Cap
- INCY 17.0B
- TLN 19.1B
- IPO Year
- INCY 1993
- TLN N/A
- Fundamental
- Price
- INCY $91.48
- TLN $407.26
- Analyst Decision
- INCY Buy
- TLN Strong Buy
- Analyst Count
- INCY 19
- TLN 12
- Target Price
- INCY $81.73
- TLN $412.00
- AVG Volume (30 Days)
- INCY 1.7M
- TLN 848.1K
- Earning Date
- INCY 10-28-2025
- TLN 11-05-2025
- Dividend Yield
- INCY N/A
- TLN N/A
- EPS Growth
- INCY 900.04
- TLN N/A
- EPS
- INCY 4.37
- TLN 3.80
- Revenue
- INCY $4,584,996,000.00
- TLN $2,128,000,000.00
- Revenue This Year
- INCY $16.41
- TLN $11.82
- Revenue Next Year
- INCY $10.86
- TLN $79.55
- P/E Ratio
- INCY $20.90
- TLN $107.24
- Revenue Growth
- INCY 18.87
- TLN 1.09
- 52 Week Low
- INCY $53.56
- TLN $158.08
- 52 Week High
- INCY $92.86
- TLN $451.28
- Technical
- Relative Strength Index (RSI)
- INCY 67.77
- TLN 49.80
- Support Level
- INCY $84.38
- TLN $352.64
- Resistance Level
- INCY $92.86
- TLN $417.09
- Average True Range (ATR)
- INCY 2.44
- TLN 17.91
- MACD
- INCY 0.35
- TLN -5.69
- Stochastic Oscillator
- INCY 86.26
- TLN 56.22
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.